Next Article in Journal
Glycosaminoglycan-Inspired Biomaterials for the Development of Bioactive Hydrogel Networks
Next Article in Special Issue
A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging
Previous Article in Journal
Higher Levels of Low Molecular Weight Sulfur Compounds and Homocysteine Thiolactone in the Urine of Autistic Children
Previous Article in Special Issue
Approaches to PET Imaging of Glioblastoma
Open AccessReview

PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape

1
Nuclear Medicine Department, and Neuroimaging Center, Technical University of Munich, 81675 Munich, Germany
2
Department of Nuclear Medicine, Philipps-University of Marburg, 35043 Marburg, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Peter Brust
Molecules 2020, 25(4), 977; https://doi.org/10.3390/molecules25040977
Received: 5 January 2020 / Revised: 17 February 2020 / Accepted: 17 February 2020 / Published: 21 February 2020
(This article belongs to the Special Issue Radiolabelled Molecules for Brain Imaging with PET and SPECT)
Ironically, population aging which is considered a public health success has been accompanied by a myriad of new health challenges, which include neurodegenerative disorders (NDDs), the incidence of which increases proportionally to age. Among them, Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common, with the misfolding and the aggregation of proteins being common and causal in the pathogenesis of both diseases. AD is characterized by the presence of hyperphosphorylated τ protein (tau), which is the main component of neurofibrillary tangles (NFTs), and senile plaques the main component of which is β-amyloid peptide aggregates (Aβ). The neuropathological hallmark of PD is α-synuclein aggregates (α-syn), which are present as insoluble fibrils, the primary structural component of Lewy body (LB) and neurites (LN). An increasing number of non-invasive PET examinations have been used for AD, to monitor the pathological progress (hallmarks) of disease. Notwithstanding, still the need for the development of novel detection tools for other proteinopathies still remains. This review, although not exhaustively, looks at the timeline of the development of existing tracers used in the imaging of Aβ and important moments that led to the development of these tracers. View Full-Text
Keywords: Alzheimer’s disease; Parkinson’s disease; β-amyloid plaques; neurofibrillary tangles; α-synucleinopathy; positron emission tomography (PET); diagnostic imaging probes Alzheimer’s disease; Parkinson’s disease; β-amyloid plaques; neurofibrillary tangles; α-synucleinopathy; positron emission tomography (PET); diagnostic imaging probes
Show Figures

Figure 1

MDPI and ACS Style

Uzuegbunam, B.C.; Librizzi, D.; Hooshyar Yousefi, B. PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape. Molecules 2020, 25, 977.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop